Medtronic achieves CE Mark approval for BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson’s through innovative brain-computer interface technology

Revolutionizing Parkinson’s Treatment:⁤ BrainSense™ Adaptive Deep Brain stimulation Gains European Approval

january ⁤13, 2025

In a groundbreaking development for Parkinson’s disease treatment, Medtronic has secured CE Mark ⁣approval for its BrainSense™ ⁣Adaptive Deep Brain Stimulation (aDBS) system and BrainSense™ electrode identifier ‍(EI) in the European Union and the ​United Kingdom.this milestone introduces the world’s only closed-loop DBS system, offering real-time, self-adjusting brain stimulation⁢ tailored to the unique needs of⁣ Parkinson’s patients.

For decades,deep brain stimulation (DBS) has been a lifeline for those battling Parkinson’s,using electrical signals to alleviate debilitating symptoms. However, the newly approved BrainSense™ aDBS takes this ​a step further. By dynamically adapting to a patient’s brain activity in real-time, this innovative therapy ensures personalized treatment both in clinical⁢ settings and everyday life. Accompanying this advancement is the BrainSense™ Electrode Identifier, which ⁤streamlines the initial programming process, ensuring optimal contact selection in less​ time.

Parkinson’s Disease: ‌A Daily ⁢Struggle

Parkinson’s disease affects over 1.2 million people in Europe and more than 10 million globally.the‌ condition disrupts mobility, ​speech, sleep, and independence, often making even simple tasks—like drinking‍ a cup of coffee or holding a loved one’s hand—seem insurmountable. For caregivers, the emotional and physical toll can be equally overwhelming.

“BrainSense™ technology⁤ is at the center of personalizing DBS‍ therapy, and we are advancing this ⁤capability through innovation that builds on our sensing-enabled DBS platform,” said Paolo Di Vincenzo, president of the Neuromodulation business at Medtronic. “From ⁣improved‍ precision for contact selection ⁢to automatically adjusting​ DBS therapy, these milestones‌ mark significant advancements in our ability to customize care for people with parkinson’s, and we’re just getting started.”

How BrainSense™ Works

The Medtronic Percept™ ​DBS system, powered ⁤by BrainSense™ technology, records and analyzes brain ⁢signals to deliver therapies tailored to each patient’s neurological patterns. This integration of brain-computer interface (BCI) technology into DBS therapy represents a leap forward in prevention, detection, diagnosis, rehabilitation, and restoration for individuals with complex neurological conditions.

“Adaptive deep brain stimulation represents an exciting evolution in how we manage Parkinson’s,” remarked Martijn Beudel, ‍MD, PhD, ⁤a neurologist‍ at Amsterdam University Medical Center, who performed ‍the first programming of the‍ system.“This⁢ technology not only enhances ⁣treatment efficacy ⁤but also empowers patients to reclaim their lives.”

A Brighter‍ Future for Parkinson’s Patients

The approval⁢ of⁢ BrainSense™ aDBS and Electrode identifier marks a significant step forward in personalized neurological care. By offering real-time adjustments and streamlined programming,these innovations promise to improve the quality of life for millions ⁤of Parkinson’s patients and ‍their caregivers.

As Medtronic continues to lead the charge in DBS​ therapy, the focus remains​ on advancing technology that not only treats symptoms but transforms lives. With ⁣BrainSense™,the future of parkinson’s care is brighter than ever.

Revolutionizing Parkinson’s Treatment: The Breakthrough of Adaptive Deep brain Stimulation

Parkinson’s disease, a progressive neurological disorder, has long posed significant challenges for patients and clinicians alike. However, recent advancements in deep brain stimulation (DBS) technology are offering⁢ new hope. Medtronic’s brainsense™ Adaptive DBS (aDBS) ⁤is at the forefront of this innovation, providing ⁢a personalized approach to managing Parkinson’s‌ symptoms by dynamically adjusting‌ stimulation based on ‌real-time brain activity.

What Makes BrainSense™ aDBS Different?

Conventional continuous deep brain stimulation (cDBS) has⁤ been a cornerstone of parkinson’s‌ treatment for decades. While ‍effective, it operates on a⁤ fixed stimulation pattern, which may not always align⁢ with a patient’s fluctuating needs. BrainSense™ aDBS, on the other hand, uses advanced sensing technology to ⁣monitor brain signals and automatically adjust stimulation levels. This adaptive approach ‌ensures that patients receive the right amount of⁣ stimulation​ at the right time, enhancing symptom control and improving ‌quality​ of life.

“By using real-time brain activity to automatically adjust stimulation, this technology enhances the ability to deliver patient-specific stimulation that can be adapted to an individual’s unique ‍needs,” said Dr. Martijn Beudel, MD, PhD, neurologist and associate professor at Amsterdam University Medical‍ Center.

The ADAPT-PD Trial: A Landmark Study

The⁢ Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) trial is one ‌of the most extensive⁣ studies to date ​on aDBS. conducted‍ across multiple global centers, this trial compared the safety and effectiveness of dual- and single-threshold aDBS ⁢modes to traditional cDBS.The study involved collaboration with leading neurologists and neurosurgeons, making it the largest and longest ⁤assessment of ​aDBS ⁢in both clinical and home​ settings.

Findings from the ADAPT-PD trial were published in npj Parkinson’s Disease, a journal within the prestigious‌ Nature ⁢Portfolio. The​ results highlight the potential of aDBS to address challenging motor symptoms and‍ improve daily disease ⁤management, offering a transformative impact on Parkinson’s care.

BrainSense™ electrode Identifier: precision Redefined

Another groundbreaking innovation is the BrainSense™ Electrode ⁣Identifier (EI), which revolutionizes the programming process for‌ DBS therapy. By analyzing local⁢ field potentials ‌(LFP) and alpha-beta activity, this technology provides clinicians with a ​detailed ‌map of a patient’s brain ‌signals. This allows‍ for precise identification of the optimal contact location, considerably reducing the time and ambiguity associated with traditional monopolar reviews.

“brainsense™ Electrode Identifier allows clinicians ​to now conduct an accurate and precise initial programming, offering a level of⁢ personalization unmatched in the field,”​ said Domenico⁤ De Paolis, vice president of Neuromodulation International at Medtronic.

A New Era in Parkinson’s‌ Care

The CE Mark ‌approval of BrainSense™ aDBS marks a significant milestone in the treatment of Parkinson’s disease. With its ability to ⁣adapt ​to ‌individual patient ⁢needs and improve symptom management,this technology is set to transform lives. medtronic, a pioneer in DBS therapy since 1987, has already impacted over 185,000 patients across 70 countries. The introduction of BrainSense™ aDBS and Electrode Identifier further⁢ solidifies its commitment to advancing neurological care.

As Dr. Alan ‍Whone, PhD, professor of movement disorders neurology at the University of Bristol, aptly put it, “The CE Mark approval of BrainSense™ ​Adaptive DBS is a critical‍ advancement in how we treat Parkinson’s disease.Its potential to address⁢ certain challenging motor ⁣symptoms and improve day-to-day disease management offers new hope ‌for patients and their families.”

Looking Ahead

With these innovations, Medtronic is⁤ not only enhancing the effectiveness‍ of DBS ⁤therapy but also paving the way for⁣ a more personalized and patient-centric approach to Parkinson’s treatment. As the ⁣technology continues to evolve, the future looks promising for patients and‌ their families, offering a brighter outlook in the fight against this debilitating disease.

Medtronic: Pioneering Healthcare Innovations That transform Lives

Medtronic, a global leader in healthcare technology, is revolutionizing the way we approach⁢ medical treatments. With‌ a mission to alleviate pain, restore health, and extend ⁢life, the company is at the ‌forefront of developing cutting-edge technologies that address some of the most complex health challenges worldwide. From cardiac devices to surgical robotics, insulin pumps, and patient monitoring systems, ⁤Medtronic’s innovations are transforming lives every second of⁣ every day.

Engineering the Remarkable

Headquartered in Galway, Ireland, Medtronic operates in over 150 ​countries, employing⁣ more than 95,000 ⁢passionate individuals dedicated to improving healthcare outcomes. The company’s diverse portfolio includes therapies for ⁤70 health conditions, ensuring that patients receive personalized, effective care. ⁢Whether it’s through advanced surgical tools or groundbreaking monitoring systems, medtronic is ‌committed to delivering solutions that prioritize patient well-being.

“Our‍ Mission —⁤ to alleviate pain, ‌restore health, ⁢and​ extend ⁢life — unites a global team of 95,000+ passionate people across more than​ 150 countries.”

Deep Brain Stimulation:‌ A Leap Forward in Parkinson’s Treatment

One of Medtronic’s most notable advancements⁣ is its Deep Brain Stimulation (DBS) technology,​ especially the Percept™ PC and Percept™ RC systems.These ⁢devices are designed to provide chronic bioelectric data, offering valuable‍ insights into a patient’s clinical status. According to recent studies, monopolar sensing​ has significantly improved the efficiency of ⁢DBS programming for Parkinson’s disease patients.

As ​Thompson et al. noted in their 2024 ⁤study, “Monopolar sensing improves the efficiency of DBS programming in Parkinson’s disease.” This breakthrough underscores Medtronic’s commitment to leveraging data-driven approaches to enhance patient care.

Adaptive DBS: The Future of Personalized Therapy

Medtronic is also pioneering Adaptive Deep Brain Stimulation (aDBS), a ‌technology ​that adjusts stimulation in real-time based on ⁢patient-specific data. While aDBS is ‍expected to be available in ‌Europe by early 2025, the company has already submitted​ an request for U.S. FDA approval. Patients considering ⁤DBS therapy are encouraged to consult​ their healthcare providers to explore the ⁢best treatment⁢ options.

Empowering Insight-driven Care

At the heart of Medtronic’s ideology is ​a dedication to insight-driven care. By combining advanced technologies with a patient-first approach, ⁣the company is setting new standards in healthcare. ‍From ‌cardiac devices that monitor heart health to surgical robotics that enhance precision, Medtronic’s innovations are designed to deliver⁣ better outcomes for individuals‍ and communities alike.

Join the Movement

To learn more about Medtronic’s ⁢groundbreaking DBS technology and other innovations, visit their website.stay updated on⁢ their latest developments by following Medtronic on LinkedIn.

Forward-Looking Statements

It’s importent​ to note that any forward-looking statements made by ⁤Medtronic are subject to risks and uncertainties,​ as outlined in the company’s ⁣periodic reports filed with the Securities and Exchange Commission. Actual results may vary from anticipated outcomes.

References

1. Thompson, J.,Radcliffe,E., ⁢Ojemann, S., ⁣et al. Monopolar sensing improves the efficiency of DBS programming in Parkinson’s disease [abstract].⁣ Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/monopolar-sensing-improves-the-efficiency-of-dbs-programming-in-parkinsons-disease/. Accessed 11/15/2024.
2. Stanslaski S, Summers RLS, Tonder L, et al. Sensing data and methodology from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s disease.

Understanding Parkinson’s Disease: Insights from Recent Research and Clinical Trials

Parkinson’s disease, ​a ‌progressive neurological disorder, continues to challenge researchers and healthcare providers worldwide. ⁣Recent advancements in clinical trials and data analysis are shedding new light on the condition, offering hope for improved​ treatments and patient outcomes. One such breakthrough is the ADAPT-PD clinical trial, which has provided valuable insights into the disease’s progression and potential therapeutic⁢ strategies.

The ADAPT-PD Clinical Trial: A Closer Look

The ADAPT-PD trial, published in NPJ Parkinson’s Disease in 2024, represents a significant step forward in understanding Parkinson’s.the⁢ study,‌ which involved a comprehensive analysis of patient⁤ data, ​highlights the importance of personalized treatment approaches. According​ to the findings, tailoring therapies to individual patient needs can ⁤significantly enhance quality of life and slow disease progression.

“The ADAPT-PD trial underscores the critical role of personalized⁣ medicine in managing Parkinson’s disease,” said a lead researcher. “By focusing on individual patient profiles, we can develop more effective​ treatment strategies.”

Global Health Insights:‌ Europe’s Perspective

In addition to clinical trials, ‍global health reports are providing a⁣ broader perspective on Parkinson’s disease. The Health at a Glance: Europe 2024 report, published by the OECD and European Commission, offers a ⁤detailed analysis of the disease’s impact across the continent. The report emphasizes ‍the ⁤need for increased funding and research to address the growing burden of Parkinson’s.

Key statistics from the report reveal that​ Parkinson’s ⁣affects millions of ​individuals in Europe, with prevalence rates‍ expected ‌to rise as the population ages. The report also highlights disparities in access to care, urging policymakers to ⁤prioritize equitable healthcare solutions.

Parkinson’s‍ Foundation: empowering Patients Through Education

The Parkinson’s Foundation continues to ⁣play a pivotal role in raising awareness ​and providing resources for patients and caregivers.‍ Their 2025 report, Statistics: Get Informed About Parkinson’s Disease with These Key Numbers, offers a comprehensive ⁣overview of the disease’s prevalence, symptoms, and treatment‍ options.

According to the foundation, early⁣ diagnosis and intervention are crucial for improving patient outcomes. They also stress the importance of ⁤ongoing research to develop ​innovative therapies and improve ⁢the quality of life for those living with Parkinson’s.

Medtronic’s Contribution ⁣to Parkinson’s Research

Medtronic, a global leader in medical technology, has been at the forefront of Parkinson’s research. Their data-driven approach has led to ‌the development of advanced therapies, including deep brain stimulation (DBS) systems, which have shown promising results in managing symptoms.

“Our commitment to innovation drives us to explore new ways to‌ improve patient care,” said a Medtronic spokesperson. “By leveraging⁢ cutting-edge technology, we aim to transform the lives ‌of those affected by Parkinson’s disease.”

Looking Ahead: The‌ Future of Parkinson’s Treatment

As research continues⁣ to evolve, the future of Parkinson’s‌ treatment looks promising. Advances in personalized ‌medicine, coupled with increased global collaboration, are paving⁣ the way for more effective therapies.Though,challenges remain,particularly in ensuring access to care for underserved populations.

For more ⁤data on Parkinson’s disease and ongoing research,‌ visit the Parkinson’s Foundation website.

Contact information

Name	Role	Contact
Naomi Rodiles	Public Relations	[phone]
Ryan Weispfenning	Investor Relations	[phone]

For media inquiries, please contact the respective representatives listed above.

How are technological advancements, such as adaptive ⁣Deep Brain Stimulation (aDBS), transforming the treatment​ landscape for Parkinson’s disease?

G valuable insights into the prevalence and management of Parkinson’s disease.According​ to a ‌2024 report by the ⁣European Parkinson’s Disease Association (EPDA), approximately 1.2 million people in Europe are living with Parkinson’s, with the number expected to rise due to aging populations. The report emphasizes the​ need for increased‍ awareness,​ early diagnosis, and‌ access to advanced therapies like Deep Brain‍ Stimulation (DBS) to improve patient outcomes.

Innovative Therapies: The Role⁣ of Technology

Technological⁣ advancements are playing a pivotal role in⁤ transforming Parkinson’s care. Adaptive Deep Brain Stimulation (aDBS),as ​pioneered‍ by Medtronic,is a prime⁣ example. This technology adjusts stimulation ‌in⁣ real-time based ⁣on patient-specific data, offering a more personalized and effective treatment approach. The recent CE mark approval ⁣of ‌Medtronic’s BrainSense™ aDBS system marks‌ a significant⁤ milestone, enabling patients in‌ Europe⁢ to benefit from this cutting-edge therapy.

“Adaptive DBS represents a paradigm shift in how we treat Parkinson’s disease,” said Dr. Alan ‍Whone, a ⁤leading neurologist. “Its ability to respond dynamically to patient⁤ needs holds immense promise ‌for improving symptom management and quality of life.”

Patient-centric Care: A Growing Focus

As research and technology continue to evolve, there is a growing emphasis on‌ patient-centric care.This approach prioritizes the unique needs and ⁤experiences‍ of patients, ensuring‍ that treatments​ are not only effective but also aligned with their lifestyles ⁣and preferences.Initiatives ⁣like the ADAPT-PD trial and the ‌development of adaptive therapies are paving the way ⁢for a ⁤more holistic and individualized ​approach to Parkinson’s treatment.

Looking to the Future

The future of Parkinson’s care is bright, with ongoing research, technological innovations, and⁢ a renewed⁤ focus on personalized ⁤medicine. As we continue to deepen our‌ understanding of the disease and develop more advanced therapies, ‍patients and their families can look forward to⁤ improved quality of life and better disease management. Collaboration between researchers, healthcare providers, and technology companies like Medtronic will⁢ be key to driving these advancements forward.

References

1. European Parkinson’s Disease Association (EPDA). (2024). Parkinson’s disease in Europe:⁤ Prevalence, Challenges, ​and Opportunities. Retrieved from https://www.epda.eu.com.
2. ADAPT-PD Clinical⁤ Trial. (2024).⁢ NPJ Parkinson’s Disease. DOI: 10.1038/s41531-024-00645-9.
3. Medtronic. (2024). BrainSense™ Adaptive DBS:⁢ Transforming Parkinson’s Care. Retrieved from https://www.medtronic.com.